bluebird bio, Inc. (BLUE) Stock

About bluebird bio, Inc.

bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.

bluebird bio, Inc. (BLUE) stock trades at $4.97 with a market capitalization of $48.67M. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-sales of 0.63. Over the past 52 weeks the stock has ranged between $3.20 and $28.60, and currently trades 82.6% below its 52-week high.

On profitability, bluebird bio, Inc. generates a return on equity (ROE) of 753.13% — well above the market average, a sign of a high-quality business, return on capital employed of 843.75%, an operating margin of -321.43%, a net profit margin of -286.90%.

Official website: www.bluebirdbio.com